Arcadia Biosciences Reports $10.7 Million Net Loss and Revenue Decline for First Half of 2026

Arcadia Biosciences, Inc. reported a net loss of $10.7 million for the six months ended June 30, 2026, a significant increase from a loss of $1.9 million during the same period in 2025. Total revenues for the first half of 2026 were $2.54 million, down 4% from $2.66 million in the prior year, primarily due to lower sales volumes and inventory challenges. The company’s operating expenses rose to $3.82 million, compared to $2.63 million in the previous year, largely driven by increased costs associated with the June 2026 Private Placement and the January 2026 Inducement Offer.

In terms of financial position, Arcadia's total assets decreased to $5.89 million as of June 30, 2026, down from $6.55 million at the end of 2025. The company’s cash and cash equivalents increased to $4.18 million, a notable rise from $259,000 at the end of the previous fiscal year. However, current liabilities also decreased to $1.65 million from $2.06 million, indicating improved liquidity management. The accumulated deficit grew to $291.9 million, reflecting ongoing operational challenges.

Strategically, Arcadia has made significant moves, including the issuance of pre-funded warrants and preferred investment options in a private placement that raised $4 million in June 2026. The company also recognized a valuation loss of $5.4 million related to this financing, reflecting the fair value of financial instruments issued exceeding gross proceeds. Additionally, the company has been actively managing its product lines, focusing on Zola coconut water, which remains its primary revenue source.

Operationally, Arcadia's engagement metrics showed a decline in product sales, with revenues from Zola coconut water decreasing by 1% year-over-year. The company has faced challenges with shipping times and inventory levels, which have impacted customer satisfaction and sales performance. As of June 30, 2026, the company had 2,181,715 shares outstanding, reflecting an increase in share count due to recent financing activities.

Looking ahead, Arcadia expressed substantial doubt about its ability to continue as a going concern, citing insufficient cash reserves to meet anticipated cash requirements for the next 12 months. The company plans to seek additional funding through debt or equity financing, although it acknowledges the risks associated with potential dilution and operational restrictions. The management is also exploring strategic alternatives, including mergers or acquisitions, to enhance its financial stability and operational capacity.